Morbidity and Mortality Weekly Report: MMWR, Volume 33U.S. Department of Health, Education, and Welfare, Public Health Service, Center for Disease Control, 1983 |
From inside the book
Results 1-5 of 100
Page 370
... W.N. CENTRAL Minn . lowa Mo. N. Dak . S. Dak . 22161 2 3 1 105 2 79 77 3 1 20 3 18 17 30 7 1832 61 27 30 20 2 6 5 11 1 1 1 7 Nebr . 8 Kans . 1 21 2 48 88 3 48 S. ATLANTIC Del . Md . 17 D.C. Va . 18 W. Va . N.C. S.C. Ga Fla . 18 037-8-5 ...
... W.N. CENTRAL Minn . lowa Mo. N. Dak . S. Dak . 22161 2 3 1 105 2 79 77 3 1 20 3 18 17 30 7 1832 61 27 30 20 2 6 5 11 1 1 1 7 Nebr . 8 Kans . 1 21 2 48 88 3 48 S. ATLANTIC Del . Md . 17 D.C. Va . 18 W. Va . N.C. S.C. Ga Fla . 18 037-8-5 ...
Page 371
... CENTRAL 616 901 3 1,412 1,436 Ohio 122 225 273 230 Ind 69 73 153 138 HI . 177 451 587 622 8 Mich 208 112 311 369 Wis . 40 40 88 77 88 OR434 242026 321 1 5 1 148 13 131 107 9 12 45 11 30 WN CENTRAL 214 201 306 369 19 Minn 65 84 52 76 ...
... CENTRAL 616 901 3 1,412 1,436 Ohio 122 225 273 230 Ind 69 73 153 138 HI . 177 451 587 622 8 Mich 208 112 311 369 Wis . 40 40 88 77 88 OR434 242026 321 1 5 1 148 13 131 107 9 12 45 11 30 WN CENTRAL 214 201 306 369 19 Minn 65 84 52 76 ...
Page 372
... CENTRAL 746 457 184 Birmingham , Ala . 155 93 32 12 MID . ATLANTIC 2,389 1,579 526 154 64 62 95 2 Chattanooga , Tenn ... W.N. CENTRAL 606 407 128 Des Moines , Iowa 34 26 6 Duluth , Minn . 20 13 4 Kansas City , Kans . 31 21 Kansas City ...
... CENTRAL 746 457 184 Birmingham , Ala . 155 93 32 12 MID . ATLANTIC 2,389 1,579 526 154 64 62 95 2 Chattanooga , Tenn ... W.N. CENTRAL 606 407 128 Des Moines , Iowa 34 26 6 Duluth , Minn . 20 13 4 Kansas City , Kans . 31 21 Kansas City ...
Page 383
... W.N. CENTRAL 20 16 19,626 21,088 13 Minn . 5 3 6 2,883 2,999 lowa 1 7 2,215 2,347 Mo. 9,452 10,293 N. Dak . S. Dak 191 214 510 594 Nebr . 1,302 1,244 3362 '21 10 1 23 ' 622 - 2''2 1 9351 2200 62 22 ' Kans . 3 3,073 3,397 S. ATLANTIC 292 ...
... W.N. CENTRAL 20 16 19,626 21,088 13 Minn . 5 3 6 2,883 2,999 lowa 1 7 2,215 2,347 Mo. 9,452 10,293 N. Dak . S. Dak 191 214 510 594 Nebr . 1,302 1,244 3362 '21 10 1 23 ' 622 - 2''2 1 9351 2200 62 22 ' Kans . 3 3,073 3,397 S. ATLANTIC 292 ...
Page 385
... CENTRAL 629 923 1,441 1,479 Ohio 129 238 278 242 Ind . 74 73 159 138 III . 177 458 603 652 Mich . 208 113 311 369 Wis . 41 41 90 78 3-2 29644 242026 163 14 145 13 112 11 11 12 46 11 32 WN CENTRAL 215 205 317 382 25 25 434 Minn . 65 85 ...
... CENTRAL 629 923 1,441 1,479 Ohio 129 238 278 242 Ind . 74 73 159 138 III . 177 458 603 652 Mich . 208 113 311 369 Wis . 41 41 90 78 3-2 29644 242026 163 14 145 13 112 11 11 12 46 11 32 WN CENTRAL 215 205 317 382 25 25 434 Minn . 65 85 ...
Other editions - View all
Common terms and phrases
Acquired Immunodeficiency Syndrome age group Alaska animal antibody Ariz Calif cancer Centers for Disease City Civilian clinical Colo Congenital rubella syndrome Conn cryptosporidiosis death Department of Health Disease Control E.S. CENTRAL Editorial Note Encephalitis Epidemiologic exposure Gonorrhea Guam Hawaii hemophilia Hepatitis hospital human illness immunization Immunodeficiency Syndrome AIDS increased infants infection influenza isolates Kans Legionellosis Leptospirosis lowa Malaria Mass measles MID ATLANTIC Minn MMWR Mortality Weekly Report Mumps Nebr NIOSH occurred Ohio Okla Oreg outbreak Pa.t Pac Trust Terr PACIFIC patients persons Pertussis Poliomyelitis population Primary & Secondary Psittacosis Public Health rabies Reporting Area risk RMSF Rubella specified notifiable diseases surveillance symptoms Syphilis Tenn tick-borne Total Toxic Shock syndrome Trichinosis Tuberculosis Tularemia Typhus fever U.S. Government Printing Unavailable TABLE United Upstate Utah vaccine Viral virus Wash weeks ending WN CENTRAL
Popular passages
Page 11 - National Center for Health Statistics. NCHS growth curves for children birth- 18 years. United States. Rockville, MD: National Center for Health Statistics. 1977. (Vital and health statistics. Series 1 1: Data from the National Health Survey, no.
Page 397 - Corticosteroids, other immunosuppressive agents, and immunosuppressive illnesses can interfere with the development of active immunity and predispose the patient to developing rabies. Immunosuppressive agents should not be administered during postexposure therapy, unless essential for the treatment of other conditions. When rabies post-exposure prophylaxis is administered to persons receiving steroids or other immunosuppressive therapy, it is especially important that serum be tested for rabies antibody...
Page 633 - ... authority to convey the warnings to the vaccinee, parent, guardian, or other responsible person of the possibility of vaccine-associated paralysis, particularly to susceptible family members and other close personal contacts. The Centers for Disease Control report that during 1972 to 1983, approximately 278.8 million OPV doses were distributed in the United States. During this same period, 87 vaccine-associated cases in apparently immunologically normal individuals were reported. Thirty-two occurred...
Page 397 - Two cases of neurologic illness resembling Guillain-Barre syndrome*'* a transient neuroparalytic illness, that resolved without sequelae in 12 weeks and a focal subacute central nervous system disorder temporally associated with HDCV, have been reported.
Page 437 - In: Remington JS, Klein JO, eds. Infectious diseases of the fetus and newborn infant. Philadelphia: WB Saunders, 1983:636-678.
Page 597 - Human cryptosporidiosis in immunocompetent and immunodeficient persons: studies of an outbreak and experimental transmission.
Page 397 - Once initiated, rabies prophylaxis should not be interrupted or discontinued because of local or mild systemic adverse reactions to rabies vaccine. Usually such reactions can be successfully managed with anti-inflammatory and antipyretic agents (eg aspirin). Reactions after vaccination with HDCV are less common than with previously available vaccines.
Page 398 - ... Category C. Animal reproduction studies have not been conducted with IMOVAX RABIES Vaccine. It is also not known whether the product can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Rabies vaccine should be given to a pregnant woman only if clearly needed. Because of the potential consequences of inadequately treated rabies exposure and limited data that indicate that fetal abnormalities have not been associated with rabies vaccination, pregnancy...
Page 557 - Hypertension detection and follow-up program cooperative group. Fiveyear findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension.
Page 392 - ... bite a person should be captured and observed for symptoms of rabies for 10 days. If symptoms do not develop, the animal may be assumed to be non-rabid. If the animal dies or is killed, its head, undamaged, should be sent promptly, under refrigeration but not frozen, to a public health laboratory. Any wild animal that bites or scratches a person should be killed at once and the head kept under refrigeration during transportation to a public health laboratory. Rubber gloves should be worn by the...